Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 May 29;19(5):e0303869. doi: 10.1371/journal.pone.0303869

Correlation between novel inflammatory markers and carotid atherosclerosis: A retrospective case-control study

Man Liao 1, Lihua Liu 1, Lijuan Bai 1, Ruiyun Wang 1, Yun Liu 1, Liting Zhang 1, Jing Han 1, Yunqiao Li 1,*, Benling Qi 1,*
Editor: Elvan Wiyarta2
PMCID: PMC11135694  PMID: 38809853

Abstract

Objective

Carotid atherosclerosis is a chronic inflammatory disease, which is a major cause of ischemic stroke. The purpose of this study was to analyze the relationship between carotid atherosclerosis and novel inflammatory markers, including platelet to lymphocyte ratio (PLR), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to neutrophil ratio (PNR), neutrophil to lymphocyte platelet ratio (NLPR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI), in order to find the best inflammatory predictor of carotid atherosclerosis.

Method

We included 10015 patients who underwent routine physical examinations at the physical examination center of our hospital from January 2016 to December 2019, among whom 1910 were diagnosed with carotid atherosclerosis. The relationship between novel inflammatory markers and carotid atherosclerosis was analyzed by logistic regression, and the effectiveness of each factor in predicting carotid atherosclerosis was evaluated by receiver operating characteristic (ROC) curve and area under the curve (AUC).

Result

The level of PLR, LMR and PNR in the carotid atherosclerosis group were lower than those in the non-carotid atherosclerosis group, while NLR, NLPR, SII, SIRI and AISI in the carotid atherosclerosis group were significantly higher than those in the non-carotid atherosclerosis group. Logistic regression analysis showed that PLR, NLR, LMR, PNR, NLPR, SII, SIRI, AISI were all correlated with carotid atherosclerosis. The AUC value of NLPR was the highest, which was 0.67, the cut-off value was 0.78, the sensitivity was 65.8%, and the specificity was 57.3%. The prevalence rate of carotid atherosclerosis was 12.4% below the cut-off, 26.6% higher than the cut-off, and the prevalence rate increased by 114.5%.

Conclusion

New inflammatory markers were significantly correlated with carotid atherosclerosis, among which NLPR was the optimum inflammatory marker to predict the risk of carotid atherosclerosis.

Introduction

Cardiovascular was always the main cause of premature death and rising healthcare costs [1, 2]. From 1990 to 2019, the total number cardiovascular disease cases has nearly doubled globally, while the number of cases and deaths from peripheral artery disease tripled [3]. Atherosclerosis, a major pathological process in most cardiovascular diseases, which may occuar as early as childhood and remain latent in the body for a long time [4]. Early detection of arterial disease in seemingly healthy individuals focuses on the peripheral arteries, especially the carotid arteries [5]. In clinical practice, carotid atherosclerosis (CAS) is the earlier and most easily detected form of atherosclerosis. Besides, carotid atherosclerotic plaque is an independent risk factor for stroke and coronary heart disease [6]. Atherosclerosis is widely recognized as a chronic inflammatory disease of the blood vessels caused by the accumulation of low density lipoprotein cholesterol [7]. Chronic inflammation is a low-grade, non-infectious, systemic inflammatory state that is associated with age, psychology, environment, lifestyle, and the resolution of acute inflammation [8]. Chronic inflammation is associated with endothelial dysfunction, leukocyte recruitment, transformation of monocytes into macrophages and eventually into foam cells, smooth muscle cell migration and other processes [7]. Chronic inflammation is involved in the whole process of the occurrence and development of atherosclerosis and is the core of atherosclerosis.

In clinical practice, peripheral blood cell count is often used as a predictor and evaluation factor for the severity of inflammation and treatment outcome of acute inflammatory diseases, such as lung infection and sepsis. Platelet to lymphocyte ratio (PLR), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to neutrophil ratio (PNR), neutrophil to lymphocyte platelet ratio (NLPR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI) are commonly used blood cell count derived values in clinical practice, also known as novel inflammatory markers. These novel inflammatory markers have repeatedly demonstrated their potential value in the early prediction and prognosis of cardiovascular disease [914]. However, the relationship between these readily available inflammation markers and atherosclerosis, especially carotid atherosclerosis, has not yet been clear, which nedds further research to be confirmed.

Therefore, this study aimed to explore the correlation between novel inflammatory markers and CAS, in order to find a better early warning indicator of clinical carotid atherosclerosis.

Method

Study design

This is a retrospective case-control study. All methods were carried out in accordance with relevant guidelines and regulations and no important aspects of the study have been omitted. Patients’ personal information is being kept confidentially. The study complies with the Declaration of Helsinki and the ethical approval of the study was obtained from the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at Sep. 4th 2023 ([2023]ID:0611). The ethics committee exempted the need for informed consent.

Population

In this study, we included 14,115 patients who underwent routine physical examinations at our physical examination center from January 2016 to December 2019. The first time we accessed the data was on September 10, 2023. The following were the inclusion criteria for this study: (1) Age>18 years; (2) People who have underwent carotid vascular ultrasound. The exclusion criteria of participants were as follows: (1) Receiving or being receiving anti-inflammatory therapy within 6 months; (2) Critically ill patients with unstable vital signs; (3) Have received or are receiving glucocorticoid therapy within 6 months; (4) Incomplete clinical data or incomplete personal information. After screening, a total of 10015 patients were included and divided into CAS group and non-CAS group according to diagnosis.

Collected clinical data and laboratory indicators and definition of inflammatory markers

Age, gender, height, and weight of the patient at admission were obtained from the hospital electronic system, and BMI was calculated according to BMI = weight/height ^2. Proper amount of venous blood was extracted by professional nurses with nursing qualification during the fasting period and sent to the laboratory for analysis to obtain white blood cell count (WBC), neutrophil count (NC), lymphocyte count (LC), monocyte count (MC), platelet (PLT), neutrophil percentage (NP), lymphocyte percentage (LP), monocyte percentage (MP), PLR, NLR, LMR, PNR, NLPR, SII, SIRI, AISI and biochemical index, such as aspartate aminotransferase (AST), triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), uric acid (UA), urea nitrogen (BUN), creatinine. The estimated glomerular filtration rate (eGFR) was calculated based on the modified MDRD equation. SIRI was defined as neutrophil count*monocyte count/lymphocyte count. SII was calculated using the formula: NLR*platele. AISI was calculated using the formula: (neutrophil count*monocyte count*platelet)/lymphocyte count. NLPR was calculated using the formula: neutrophil count*100/lymphocyte count*platelet. Comorbidity, smoking history and drinking history were obtained from the patient’s personal history.

Diagnostic criteria for carotid atherosclerosis

Carotid atherosclerosis is diagnosed in one of the following situations: (1) A clear history of atherosclerosis or revascularization treatment; (2) Carotid artery ultrasound showed atherosclerotic plaque or carotid intima-media thickness of 1.0mm or more [5].

Statistical analysis

Shapiro-Wilkstest is used to test whether the continuous variables obey normal distribution, and the continuous variables with normal distribution are represented by mean ± standard deviation (SD). Continuous variables that are not normally distributed are expressed as medians with interquartile range (IQR). The categorical variable is represented by number with percentages (%). ANOVA tests (conforming to normal distribution) and Kruskal-Wallis tests (non-conforming to normal distribution) were used for the differences between of continuous data among CAS and non-CAS. Chi-square test was used to compare the difference of Categorical data between patients with CAS and non-CAS. Logistic regression analysis was used to evaluate the correlation between various inflammatory indicators and CAS after adjusting factors such as age, gender, BMI, serum biochemical indicators and clinical diagnosis and other factors. In Logistic regression analysis, forward selection method was used to identify CAS risk factors. Finally, the efficiency of each inflammatory markers to CAS was evaluated by receiver operating characteristic (ROC) curve. P<0.05 was considered to be statistically significant. All statistical analyses and diagrams were done using SPSS (version 23.0) or R language.

Result

Clinical baseline data

A total of 10015 patients aged 18–94 were enrolled in the study, including 1910 (19.1%) in the CAS group. Table 1 shows the baseline characteristics between the two groups. There were no significant differences in BMI, PLR and dyshepatia between the two groups (P>0.05). While age, gender, WBC, NC, LC, MC, PLT, NP, LP, MP, NLR, LMR, PNR, NLPR, SII, SIRI, AISI, AST, TG, TC, HDL_C, LDL_C, BUN, creatinine, eGFR, UA, smoking history, drinking history, renaldysfuncyion, hyperuricemia, fatty liver, dyslipidemia, hypertension, diabetes and osteoporosis were significantly different between the two groups(P<0.05).

Table 1. Baseline characteristics between CAS and non-CAS.

Non-CAS CAS P value
N(%) 8105(80.9) 1910(19.1)
Age,year 43.21 ± 12.65 66.12 ± 12.07 0.000
Male, N(%) 5105(63.0) 1605(84.0) 0.000
BMI, Kg/m2 23.80 ± 3.30 24.53 ± 3.19 0.148
WBC 6.11 ± 1.46 6.29 ± 1.59 0.000
NC 3.50 ± 1.09 3.78 ± 1.25 0.000
LC 2.08 ± 0.55 1.91 ± 0.56 0.000
MC 0.36 ± 0.12 0.39 ± 0.13 0.000
PLT 235.57 ± 54.26 212.40 ± 52.94 0.000
NP 56.69 ± 7.44 59.51 ± 7.82 0.000
LP 34.48 ± 7.05 31.04 ± 7.44 0.000
MP 5.95 ± 1.53 6.35 ± 1.67 0.000
PLR 120.07 ± 38.23 118.90 ± 41.34 0.239
NLR 1.76 ± 0.61 2.12 ± 0.91 0.000
LMR 6.19 ± 2.10 5.24 ± 1.93 0.000
PNR 72.54 ± 24.68 60.64 ± 20.90 0.000
NLPR 0.78 ± 0.31 1.06 ± 0.54 0.000
SII 418.42 ± 188.35 452.74 ± 237.00 0.000
SIRI 0.65 ± 0.36 0.86 ± 0.56 0.000
AISI 156.07 ± 104.87 186.33 ± 137.93 0.000
TP, g/L 74.86 ± 4.12 74.35 ± 4.40 0.000
Albumin, g/L 47.27 ± 2.54 46.30 ± 2.68 0.000
Globulin, g/L 27.58 ± 3.31 28.05 ± 3.77 0.000
AGR 1.74 ± 0.23 1.68 ± 0.25 0.000
AST, U/L 25.80 ± 19.48 24.48 ± 18.33 0.008
TG, mmol/L 1.58 ± 1.23 1.65 ± 1.09 0.016
TC, mmol/L 4.75 ± 0.86 4.84 ± 1.01 0.000
HDL_C, mmol/L 1.40 ± 0.34 1.37 ± 0.33 0.000
LDL_C, mmol/L 2.74 ± 0.70 2.84 ± 0.83 0.000
BUN, mmol/L 4.76 ± 1.21 5.65 ± 1.54 0.000
Creatinine, umol/L 71.46 ± 14.61 79.76 ± 19.64 0.000
eGFR, mL/min/1.73m2 109.06 ± 22.75 93.81 ± 22.49 0.000
Uric acid, mmol/L 363.82 ± 96.91 375.34 ± 88.49 0.000
Smoking history,N(%) 2642(32.6) 830(43.5) 0.000
Drinking history,N(%) 1901(23.5) 591(30.9) 0.000
Renaldysfuncyion,N(%) 31(0.4) 103(5.4) 0.000
Dyshepatia,N(%) 83(1.0) 13(0.7) 0.166
Dyslipidemia,N(%) 5231(64.5) 1402(73.4) 0.000
Hyperuricemia,N(%) 4044(49.9) 1096(57.4) 0.000
Fatty liver,N(%) 2484(30.6) 718(37.6) 0.000
Diabetes,N(%) 339(4.2) 297(15.5) 0.000
Osteoporosis,N(%) 745(9.2) 446(23.4) 0.000
Hypertension,N(%) 1581(19.5) 835(43.7) 0.000

Continuous variables are presented as mean ± S.D. Categorical data are presented as number (percentages).

CAS, carotid atherosclerosis; BMI, body mass index; WBC, white blood cell; NC, neutrophil count; LC, lymphocyte count; MC, monocyte count; PLT, platelet; NP, neutrophil percentage; LP, lymphocyte percentage; MP, monocyte percentage; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PNR, platelet to neutrophil ratio; NLPR, neutrophil to lymphocyte platelet ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; AISI, aggregate index of systemic inflammation; TP, total protein; AGR, albumin-globulin ratio; AST, aspartate aminotransferase; TG, triglyceride; TC, total cholesterol; HDL_C, high density lipoprotein cholesterol; LDL_C, low density lipoprotein cholesterol; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate.

Relationship between novel inflammatory markers and CAS

The relationship between novel inflammation markers and CAS was observed by spline smoothing plot, shown in Fig 1. LMR, PNR were negatively correlated with CAS, while PLR, NLR, NLPR, SII, SIRI, AISI, NLPR were positively correlated with CAS.

Fig 1. Spline smoothing plot between novel inflammation markers and carotid atherosclerosis.

Fig 1

A non- linear relationship between novel inflammation markers and carotid atherosclerosis after adjusting for age, gender, body mass index, aspartate aminotransferase, triglyceride, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, estimated glomerular filtration rate, uric acid, hypertension, diabetes, osteoporosis, fatty liver, smoking history, drinking history. CAS, carotid atherosclerosis; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PNR, platelet to neutrophil ratio; NLPR, neutrophil to lymphocyte platelet ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; AISI, aggregate index of systemic inflammation.

Logistic regression analysis of CAS

Univariate logistic regression analysis of the relationship between inflammatory markers and CAS showed the same difference as that between the two groups. Furthermore, after adjusting for many possible confounders such as age, sex, BMI, all inflammatory markers were statistically significant (P<0.05) with CAS. These infalmmatory markers have varying effects on CAS, and the risk value of NLPR is much higher than other markers (OR = 2.35). Their CAS risk value and forest plot were shown in Fig 2.

Fig 2. The ORs and 95% CI of novel inflammatory indicators to CAS risk by logistic regression.

Fig 2

Model 1 adjusted for none. Model 2 adjusted for age, sex, and body mass index. Model 3 adjusted for age, gender, body mass index, aspartate aminotransferase, triglyceride, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, estimated glomerular filtration rate, uric acid, hypertension, diabetes, osteoporosis, smoking history, drinking history. Forest plot of novel inflammatory markers for carotid atherosclerosis risk after adjusting for Model 3. PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PNR, platelet to neutrophil ratio; NLPR, neutrophil to lymphocyte platelet ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; AISI, aggregate index of systemic inflammation.

The efficacy of inflammatory markers to predict CAS was assessed by ROC curve. After adjusting for confounding factors, there were still statistical differences in all inflammatory markers. The ROC curve to evaluate the effectiveness of the above markers in CAS diagnosis is shown in Table 2 and Fig 3. The AUC values of NLR, SII, SIRI, AISI and NLPR were all in the range of 0.5–0.7. The highest AUC value for NLPR recognition of CAS is 0.67. And NLPR uses the adjusted predictive value of Model 3 to identify the AUC value of CAS as 0.91. The cut-off value calculated by Youden index was that NLPR was 0.78, that the sensitivity was 65.8%, and that the specificity was 57.3%. The prevalence rate of carotid atherosclerosis was 12.4% below the cut-off, 26.6% higher than the cut-off, and the prevalence rate increased by 114.5%.

Table 2. Evaluation of the predictive effect of the novel inflammatory markers on risk of CAS by ROC curves.

AUC (95%CI) Specificity Sensitivity Cut-off Youden’s index
PLR 0.52 (0.50,0.53)a 0.76 0.28 92.41 0.04
NLR 0.62(0.60,0.63)a 0.69 0.47 1.96 0.16
LMR 0.64(0.62,0.65)a 0.68 0.51 5.02 0.19
PNR 0.65(0.63,0.66)a 0.64 0.57 61.24 0.21
SII 0.53(0.52,0.55)a 0.84 0.23 571.56 0.07
SIRI 0.63(0.62,0.64)a 0.69 0.50 0.72 0.19
AISI 0.57(0.55,0.58)a 0.66 0.45 163.70 0.11
NLPR 0.67(0.65,0.68)a 0.57 0.66 0.78 0.23
Model 3-NLPR 0.91(0.90,0.91)a 0.80 0.85 0.18 0.65

CAS, carotid atherosclerosis; ROC, receiver operating curve; AUC, area under the curve; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PNR, platelet to neutrophil ratio; NLPR, neutrophil to lymphocyte platelet ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; AISI, aggregate index of systemic inflammation.

aP<0.05.

Fig 3. Receiver operating characteristic (ROC) curves of all inflammatory markers for identifying carotid atherosclerosis risk.

Fig 3

PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PNR, platelet to neutrophil ratio; NLPR, neutrophil to lymphocyte platelet ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; AISI, aggregate index of systemic inflammation.

Subgroup analyses between NLPR and CAS

In order to study the CAS risk and interaction of inflammatory markers in people with different clinicopathological characteristics. We further analyzed six subgroups of NLPR and CAS risk indicators (hyperuricemia, fatty liver, dyslipidemia, hypertension, diabetes, osteoporosis). The results showed that NLPR had the highest OR value in population without lipid metabolism abnormalities (Table 3). CAS were significantly associated with NLPR in all subgroups. The interaction among subgroups revealed that NLPR had an interaction with hyperuricemia, fatty liver, dyslipidemia, hypertension, diabetes and osteoporosis, and all of these disease subgroups significantly weakened the risk of NLPR for CAS.

Table 3. Association between NLPR and CAS in subgroups.

N(%) OR(95%CI) P interaction
Hyperuricemia 0.000
 No 4875 2.45(1.89,3.17)
 Yes 5140 2.29(1.81,2.90)
Fatty liver 0.000
 No 6813 2.59(2.07,3.25)
 Yes 3202 1.98(1.49,2.63)
Dyslipidemia 0.000
 No 3382 2.72(1.89,3.87)
 Yes 6633 2.24(1.83,2.74)
Hypertension 0.000
 No 7599 2.56(2.04,3.22)
 Yes 2416 2.14(1.64,2.81)
Diabetes 0.003
 No 9379 2.38(1.98,2.87)
 Yes 636 2.26(1.37,3.73)
Osteoporosis 0.000
 No 7755 2.55(2.08,3.13)
 Yes 1191 1.91(1.31,2.76)

Above subgroups were adjusted for age, gender, body mass index, aspartate aminotransferase, triglyceride, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, estimated glomerular filtration rate, uric acid, hypertension, diabetes, osteoporosis, smoking history, drinking history.

CAS, carotid atherosclerosis; NLPR, neutrophil to lymphocyte platelet ratio.

Discussion

Novel inflammatory markers have been proven to be closely related to various diseases, and their easy availability has important clinical value. In this cross-sectional study, we analyzed the effect of multiple inflammatory markers on CAS, where NLR, SII, SIRI, AISI, NLPR remained significant after adjusting for multiple confounding factors. At the same time, this study further evaluated the value of various inflammatory markers in predicting CAS, among which NLPR had the largest AUC value in identifying CAS risk. Compared with other inflammatory markers, NLPR has a higher value for predicting CAS which may be the best inflammatory indicator for identifying atherosclerosis.

Chronic inflammation leads to atherosclerosis and cardiovascular disease. Neutrophils are the most numerous type of white blood cell and play a major role in inflammation. Although neutrophil count is primarily used as a biomarker for acute infection and inflammation, it has also been shown to accelerate chronic inflammation [15]. Monocyte-derived macrophages are important mediators in the atherosclerotic cascade and are associated with plaque formation through infiltration into the subendothelial layer. Subsequently, uptake of LDL-C complexes leads to the formation of foam cells. In addition to plaque formation, macrophages are involved in extracellular matrix remodeling by secreting pro-inflammatory cytokines and chemokines [16]. In our study, the number of neutrophils and monocytes increased in patients with CAS compared with non-CAS patients, indicating that the higher the number of neutrophils and monocytes, the higher the incidence of CAS. In contrast, lymphocytes slow the progression of atherosclerosis [14]. Our findings were the same, with a reduced number of lymphocytes in patients with CAS, suggesting that the higher the number of lymphocytes, the lower the incidence of CAS. Platelets play two main roles in atherosclerosis: platelets directly adhere to the blood vessel wall to promote plaque formation, and platelets then release inflammatory mediators and chemokines to promote leukocyte recruitment [17]. In our results, platelet counts were reduced in patients with CAS compared to non-CAS patients. The reason for this opposite situation may be that platelets have multiple roles in the formation of atherosclerosis, and in our study, the number of platelets alone was not significantly associated with the development of carotid atherosclerosis. In subsequent binary logistic regression analysis, there was no statistical difference between platelet count and CAS risk after adjusting for confounders.

In previous studies, we found that NLR, MLR, and PLR increase the risk of arterial stiffness [18]. In recent years, LMR, PNR, NLPR, SII, SIRI, AISI and other indicators have also proved their clinical significance in cardiovascular diseases. A small sample observational study showed that the novel inflammatory markers SIRI, NLR, and LMR were associated with CAS risk in middle-aged and older men [9]. PNR have also been shown to predict mortality in patients with ischemic stroke [10]. SII was also found to be a strong independent predictor of adverse outcomes in patients with acute coronary syndromes [12]. To find the best predictors of CAS, we included these markers in a larger population study at the same time. The results showed that the NLPR had the highest accuracy in identifying the risk of CAS. NLPR is the ratio of neutrophil to lymphocyte*platelet. Initially, NLPR was found to have predictive value in tumor prognosis [19, 20]. Subsequently, NLPR was also found to be associated with the prognosis of acute kidney injury, suppurative liver abscess, severe trauma, and COVID-19 [2125]. The value of NLPR in cardiovascular disease is equally outstanding. Studies have shown that NLPR is an independent predictor of in-hospital mortality after acute type A aortic dissection [11]. A prospective cohort study found that NLPR was an independent predictor of adverse outcomes in patients with acute coronary syndrome, and patients with a higher NLRP had a higher incidence of major adverse cardiovascular events [26]. In this study, our results directly show that there is a significant correlation between NLPR and CAS, and the higher the level of NLPR, the higher the risk of CAS.

In statistical analyses of baseline characteristics, in addition to indicators of inflammation, we found a number of variables that were statistically different between the CAS and Non-CAS groups, including age, gender, AST, TG, TC, HDL_C, LDL_C, BUN, creatinine, eGFR, UA, smoking history, drinking history, renaldysfuncyion, hyperuricemia, fatty liver, dyslipidemia, hypertension, diabetes and osteoporosis. Undoubtedly, age is the number one risk factor for a wide range of chronic diseases and systemic chronic inflammatory states [8]. A significant increase in age in the CAS group was also found in our results. Some studies have shown that the incidence of atherosclerosis is higher in postmenopausal women compared to men [27]. Whereas, our results showed higher percentage of males in CAS group, which may be due to the uneven gender distribution in the total population of our medical examination, where males were significantly more than females. In addition to this, renaldysfuncyion, hyperuricaemia, fatty liver, dyslipidaemia, hypertension, diabetes, osteoporosis and history of smoking and alcohol consumption were all strongly associated with atherosclerosis [2834]. And chronic inflammation can lead to cardiovascular disease, cancer, diabetes, chronic kidney disease, non-alcoholic fatty liver disease and many other diseases [8]. In our subsequent stratified analyses, we also analysed that there was a significant interaction between these diseases and NLPR, which together contributed to the development of CAS.

In this study, we evaluated the value of multiple inflammatory markers for the risk of CAS and found the best inflammatory marker that can be easily obtained to effectively identify the risk of CAS. In addition, the relatively large sample size ensures the accuracy and reliability of the results. Nevertheless, there are some limitations to this study. First, due to the cross-sectional design of the study, a causal relationship between inflammatory markers and CAS cannot be demonstrated, so more prospective studies are needed to confirm these findings. Second, because this study was a single-center study with a relatively narrow group of participants, the findings may not be well extrapolated to other populations. Finally, although we have carefully adjusted for potential confounding factors, it is difficult to rule out potential residual confounding.

Conclusion

Atherosclerosis is a chronic inflammatory disease of the walls of blood vessels. In this study, novel inflammatory markers have good predictive effects on carotid atherosclerosis, and NLPR has the highest predictive value. NLPR can be used as a potential predictor of carotid atherosclerosis.

Supporting information

S1 Raw data

(XLSX)

pone.0303869.s001.xlsx (3.2MB, xlsx)

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

The study was supported by the National Natural Science Foundation of China (Grant No.81571373, No.81601217, No.82001491), Natural Science Foundation of Hubei Province of China (Grant No. 2017CFB627), Health Commission of Hubei Province scientific research project (Grant No. WJ2021M247) and Scientific Research Fund of Wuhan Union Hospital (Grant No.2019). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22. doi: 10.1016/S0140-6736(20)30925-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. Journal of the American College of Cardiology. 2019;74(20):2529–32. [DOI] [PubMed] [Google Scholar]
  • 3.Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. Journal of the American College of Cardiology. 2020;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.McGill HC, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong JP. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr. 2000;72(5 Suppl):1307S–15S. doi: 10.1093/ajcn/72.5.1307s [DOI] [PubMed] [Google Scholar]
  • 5.Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European heart journal. 2016;37(29):2315–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bos D, Arshi B, van den Bouwhuijsen QJA, Ikram MK, Selwaness M, Vernooij MW, et al. Atherosclerotic Carotid Plaque Composition and Incident Stroke and Coronary Events. Journal of the American College of Cardiology. 2021;77(11):1426–35. doi: 10.1016/j.jacc.2021.01.038 [DOI] [PubMed] [Google Scholar]
  • 7.Nguyen MT, Fernando S, Schwarz N, Tan JT, Bursill CA, Psaltis PJ. Inflammation as a Therapeutic Target in Atherosclerosis. Journal of clinical medicine. 2019;8(8). doi: 10.3390/jcm8081109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nature medicine. 2019;25(12):1822–32. doi: 10.1038/s41591-019-0675-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Chen Q, Che M, Shen W, Shao L, Yu H, Zhou J. Comparison of the Early Warning Effects of Novel Inflammatory Markers SIRI, NLR, and LMR in the Inhibition of Carotid Atherosclerosis by Testosterone in Middle-Aged and Elderly Han Chinese Men in the Real World: A Small Sample Clinical Observational Study. Am J Mens Health. 2023;17(3):15579883231171462. doi: 10.1177/15579883231171462 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Geng L, Zuo L, Li H, Wang Y, Zhang Q, Ran J, et al. Association of platelet-to-neutrophil ratios with 1-year outcome and mortality in patients with acute ischemic stroke. Neurosci Lett. 2023;798:137016. doi: 10.1016/j.neulet.2022.137016 [DOI] [PubMed] [Google Scholar]
  • 11.Guvenc O, Engin M. The role of neutrophil-lymphocyte platelet ratio in predicting in-hospital mortality after acute Type A aortic dissection operations. Eur Rev Med Pharmacol Sci. 2023;27(4):1534–9. doi: 10.26355/eurrev_202302_31396 [DOI] [PubMed] [Google Scholar]
  • 12.Karadeniz F, Karadeniz Y, Altuntaş E. Systemic immune-inflammation index, and neutrophilto-lymphocyte and platelet-to-lymphocyte ratios can predict clinical outcomes in patients with acute coronary syndrome. Cardiovascular journal of Africa. 2023;34:1–7. doi: 10.5830/CVJA-2023-011 [DOI] [PubMed] [Google Scholar]
  • 13.Aydin C, Engin M. The Value of Inflammation Indexes in Predicting Patency of Saphenous Vein Grafts in Patients With Coronary Artery Bypass Graft Surgery. Cureus. 2021;13(7):e16646. doi: 10.7759/cureus.16646 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Song Y, Zhao Y, Shu Y, Zhang L, Cheng W, Wang L, et al. Combination model of neutrophil to high-density lipoprotein ratio and system inflammation response index is more valuable for predicting peripheral arterial disease in type 2 diabetic patients: A cross-sectional study. Frontiers in endocrinology. 2023;14:1100453. doi: 10.3389/fendo.2023.1100453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159–75. doi: 10.1038/nri3399 [DOI] [PubMed] [Google Scholar]
  • 16.Theofilis P, Oikonomou E, Tsioufis K, Tousoulis D. The Role of Macrophages in Atherosclerosis: Pathophysiologic Mechanisms and Treatment Considerations. Int J Mol Sci. 2023;24(11). doi: 10.3390/ijms24119568 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Nording HM, Seizer P, Langer HF. Platelets in inflammation and atherogenesis. Front Immunol. 2015;6:98. doi: 10.3389/fimmu.2015.00098 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wang Y, Wang R, Bai L, Liu Y, Liu L, He L, et al. The Leukocyte Subtype Counts and Ratios Can Effectively Predict the Risk of Arterial Stiffness Assessed by Cardio-Ankle Vascular Index: A Retrospective Study. Frontiers in cardiovascular medicine. 2021;8:671885. doi: 10.3389/fcvm.2021.671885 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Albisinni S, Pretot D, Al Hajj Obeid W, Aoun F, Quackels T, Peltier A, et al. The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes. Prog Urol. 2019;29(8–9):423–31. doi: 10.1016/j.purol.2019.05.008 [DOI] [PubMed] [Google Scholar]
  • 20.Łochowski M, Łochowska B, Zawadzka I, Cieślik-Wolski B, Kozik D, Kozak J. Prognostic value of neutrophil-to-lymphocyte, platelet-to-lymphocyte and lymphocyte-to-monocyte ratio ratios in patients operated on due to non-small cell lung cancer. Journal of thoracic disease. 2019;11(8):3377–84. doi: 10.21037/jtd.2019.07.72 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Yang Z, Qiao Y, Wang D, Yan G, Tang C. Association Between Inflammatory Biomarkers and Contrast-induced Acute Kidney Injury in ACS Patients Undergoing Percutaneous Coronary Intervention: A Cross-sectional Study. Angiology. 2023:33197231185445. doi: 10.1177/00033197231185445 [DOI] [PubMed] [Google Scholar]
  • 22.Li Y, Zou Z, Zhang Y, Zhu B, Ning Y, Shen B, et al. Dynamics in perioperative neutrophil-to-lymphocyte*platelet ratio as a predictor of early acute kidney injury following cardiovascular surgery. Renal failure. 2021;43(1):1012–9. doi: 10.1080/0886022X.2021.1937220 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Li S, Yu S, Qin J, Peng M, Qian J, Zhou P. Prognostic value of platelet count-related ratios on admission in patients with pyogenic liver abscess. BMC Infect Dis. 2022;22(1):636. doi: 10.1186/s12879-022-07613-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Chae YJ, Lee J, Park JH, Han DG, Ha E, Yi IK. Late Mortality Prediction of Neutrophil-to-Lymphocyte and Platelet Ratio in Patients With Trauma Who Underwent Emergency Surgery: A Retrospective Study. J Surg Res. 2021;267:755–61. doi: 10.1016/j.jss.2020.11.088 [DOI] [PubMed] [Google Scholar]
  • 25.Fois AG, Paliogiannis P, Scano V, Cau S, Babudieri S, Perra R, et al. The Systemic Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients. Molecules. 2020;25(23). doi: 10.3390/molecules25235725 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Fan W, Wei C, Liu Y, Sun Q, Tian Y, Wang X, et al. The Prognostic Value of Hematologic Inflammatory Markers in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2022;28:10760296221146183. doi: 10.1177/10760296221146183 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Lu Y, Pechlaner R, Cai J, Yuan H, Huang Z, Yang G, et al. Trajectories of Age-Related Arterial Stiffness in Chinese Men and Women. Journal of the American College of Cardiology. 2020;75(8):870–80. doi: 10.1016/j.jacc.2019.12.039 [DOI] [PubMed] [Google Scholar]
  • 28.Essop MR, Seedat F, Raal FJ. Dyslipidaemia in patients with chronic kidney disease—a neglected cardiovascular risk factor. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 2023;113(11):35–40. doi: 10.7196/SAMJ.2023.v113i11.1089 [DOI] [PubMed] [Google Scholar]
  • 29.Yan Z, Shao T. Chronic Inflammation in Chronic Kidney Disease. Nephron. 2024;148(3):143–51. doi: 10.1159/000534447 [DOI] [PubMed] [Google Scholar]
  • 30.Wang Z, Xiao Y, Lu J, Zou C, Huang W, Zhang J, et al. Investigating linear and nonlinear associations of LDL cholesterol with incident chronic kidney disease, atherosclerotic cardiovascular disease and all-cause mortality: A prospective and Mendelian randomization study. Atherosclerosis. 2023;387:117394. doi: 10.1016/j.atherosclerosis.2023.117394 [DOI] [PubMed] [Google Scholar]
  • 31.Zhang Y, Xia Z, Cai X, Su X, Jin A, Mei L, et al. Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study. Cardiovascular diabetology. 2023;22(1):342. doi: 10.1186/s12933-023-02083-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Gu N, Liu Z, Wang Z, Shen C, Zhang W, Tian H, et al. Association Between Serum Uric Acid Levels and Neoatherosclerosis. International heart journal. 2024;65(1):4–12. doi: 10.1536/ihj.23-058 [DOI] [PubMed] [Google Scholar]
  • 33.Zhang F, Yu Z. Mendelian randomization study on insulin resistance and risk of hypertension and cardiovascular disease. Scientific reports. 2024;14(1):6191. doi: 10.1038/s41598-023-46983-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Geng G, Li Z, Wang S, Yuan T, Quan G. Association between bone mineral density and coronary plaque burden in patients with coronary artery disease: a cross-sectional study using quantitative computed tomography. Coronary artery disease. 2024;35(2):105–13. doi: 10.1097/MCA.0000000000001316 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Elvan Wiyarta

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

20 Feb 2024

PONE-D-23-42287Correlation between Novel Inflammatory Markers and Carotid Atherosclerosis: a Cross-Sectional StudyPLOS ONE

Dear Dr. qi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 05 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Elvan Wiyarta, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

"The study was supported by the National Natural Science Foundation of China (Grant No.81571373, No.81601217, No.82001491), Natural Science Foundation of Hubei Province of China (Grant No. 2017CFB627), Health Commission of Hubei Province scientific research project (Grant No. WJ2021M247) and Scientific Research Fund of Wuhan Union Hospital (Grant No.2019)."

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. In this instance it seems there may be acceptable restrictions in place that prevent the public sharing of your minimal data. However, in line with our goal of ensuring long-term data availability to all interested researchers, PLOS’ Data Policy states that authors cannot be the sole named individuals responsible for ensuring data access (http://journals.plos.org/plosone/s/data-availability#loc-acceptable-data-sharing-methods).

Data requests to a non-author institutional point of contact, such as a data access or ethics committee, helps guarantee long term stability and availability of data. Providing interested researchers with a durable point of contact ensures data will be accessible even if an author changes email addresses, institutions, or becomes unavailable to answer requests.

Before we proceed with your manuscript, please also provide non-author contact information (phone/email/hyperlink) for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If no institutional body is available to respond to requests for your minimal data, please consider if there any institutional representatives who did not collaborate in the study, and are not listed as authors on the manuscript, who would be able to hold the data and respond to external requests for data access? If so, please provide their contact information (i.e., email address). Please also provide details on how you will ensure persistent or long-term data storage and availability.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Please address all review from the reviewers below

Please also make the rebuttal letter to address each of the issue

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Authors, I want to say that this study fulfills the novelty and offers an important result. But, I am concerned about several issues in your manuscript. I think you need to explain more the main rationale of the study and explain why the variable is choosen to investigate. The other comments on the issues have been embedded in the reviewed manuscript. I hope you can revise for the improvement of your manuscript.

line 3 ....In the title the authors mention a cross sectional study design, but in the method section the authors mention the different study design

line 77 ...In the introduction section... Can the authors mention possible factors leading to chronic inflammation which especially is significant in cerebrovascular atherosclerosis?

Line 99... Can authors elaborate why and how significant this variable (CAS) is considered to be investigated in the study. I suggest the explanation can be the rationale of the selection of the CAS in this study?

Line 101..The authors should state consistently the study design

Line 109 ...Can the authors specify the inclusion criteria of subject selection in this study, it can be range of age, gender, and some specific health-related status, etc.

Line 116 ..Do the authors consider the history of TIA, diabetes, smoking history, neck blunt trauma, etc as the confounding factors or exclusion criteria?

Line 120...Please the author provide the timing of lab data collection

Line 141...Is there any temporal relationship between this medical history and the timing of lab data collection?

Line 164..These criteria of subject selection are not yet mentioned in the method section

Line 167 - 172 ...There are several variables which are different between the CAS group and non CAS group. Can the authors interpret these findings?

Line 204 ..Can the authors show the statistical analysis for adjusting these confounding factors?

Reviewer #2: I evaluated this study in which new inflammatory markers were used to predict coronary artery disease. The fact that the number of patients in the study is quite remarkable increases the power of the study. New inflammatory markers were found to be significantly correlated with carotid atherosclerosis; However, NLPR was found to be the most appropriate inflammatory marker to predict the risk of carotid atherosclerosis. These markers may be practical, accessible and inexpensive for the clinician to use in their daily routine. In general, the English language of the well-designed and written study should be reviewed.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Minor Revision.docx

pone.0303869.s002.docx (364.6KB, docx)
PLoS One. 2024 May 29;19(5):e0303869. doi: 10.1371/journal.pone.0303869.r002

Author response to Decision Letter 0


26 Mar 2024

Journal Requirements:

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Yes, I've checked that my manuscript meets PLOS ONE's style.

2.Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Response: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. I have affirmed the relevant content in my cover letter.

3.In this instance it seems there may be acceptable restrictions in place that prevent the public sharing of your minimal data. However, in line with our goal of ensuring long-term data availability to all interested researchers, PLOS’ Data Policy states that authors cannot be the sole named individuals responsible for ensuring data access (http://journals.plos.org/plosone/s/data-availability#loc-acceptable-data-sharing-methods).

Response: I'll attach my raw data to the support information.

4.Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Response: All values in the tables and images in the article are based on raw data and statistically analysed. I'll attach my raw data to the support information.

5.Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response: No changes to original references, but we have added some references.

Review Comments to the Author:

line 3 ....In the title the authors mention a cross sectional study design, but in the method section the authors mention the different study design

Response: This study can be described as both cross sectional study and retrospective case-control study, but it prefers retrospective case-control study, so we describe it uniformly as retrospective case-control study both in the title and in the method section.

line 77 ...In the introduction section... Can the authors mention possible factors leading to chronic inflammation which especially is significant in cerebrovascular atherosclerosis?

Response: Possible factors leading to chronic inflammation have been added in the preamble section.

Line 99... Can authors elaborate why and how significant this variable (CAS) is considered to be investigated in the study. I suggest the explanation can be the rationale of the selection of the CAS in this study?

Response: In line 73-76 we add an explanation of why CAS was chosen for the study.

Line 101...The authors should state consistently the study design

Response: We modify study design consistently to retrospective case-control study both in the title and in the method section.

Line 109 ...Can the authors specify the inclusion criteria of subject selection in this study, it can be range of age, gender, and some specific health-related status, etc.

Response: The population included in this study was greater than 18 years age and underwent carotid vascular ultrasound. We have added to the methods section the inclusion criteria in line 117-118.

Line 116 ...Do the authors consider the history of TIA, diabetes, smoking history, neck blunt trauma, etc as the confounding factors or exclusion criteria?

Response: We consider the history of diabetes, hypertension, smoking history, etc as the confounding factors, but the history of TIA and neck blunt trauma were not documented in our medical history and the history of TIA and neck blunt trauma are not a cause of atherosclerosis.

Line 120...Please the author provide the timing of lab data collection

Response: Clinical data and lab data were collected together, and the time of data collection is described on line 115.

Line 141...Is there any temporal relationship between this medical history and the timing of lab data collection?

Response: This study was retrospective. The medical history was recorded on the same day as the laboratory data, and we collected the history and laboratory data uniformly several years after these data existed.

Line 154...Can the authors show the statistical analysis for these confounding factors?

Response: We describe the statistical results of the confounding factors in Table 1 and calculate the differences between the two groups. However, because subsequent studies have focused on novel inflammatory indicators and adding confounding factors may affect the aesthetics of forest plots of novel inflammatory indicator ORs , the analysis of confounding factors was not continued in subsequent logistic regressions.

Line 164...These criteria of subject selection are not yet mentioned in the method section

Response: We have added to the methods section the inclusion criteria in line 117-118.

Line 167 - 172 ...There are several variables which are different between the CAS group and non CAS group. Can the authors interpret these findings?

Response: We have added a relevant explanation of this result in the discussion section in line 130-150.

Line 204...Can the authors show the statistical analysis for adjusting these confounding factors?

Response: We describe the statistical results of the confounding factors in Table 1 and calculate the differences between the two groups. However, because subsequent studies have focused on novel inflammatory indicators and adding confounding factors may affect the aesthetics of forest plots of novel inflammatory indicator ORs , the analysis of confounding factors was not continued in subsequent logistic regressions.

Line 333...The authors can explain in the discussion section about the possible interaction between the inflammatory markers and the known risk factors/comorbid according to the baseline characteristics of the subjects

Response: We have added a relevant explanation of the baseline characteristics and explained the interactions that exist between inflammatory markers and known co-morbidities in the discussion section in line 130-150.

Line 336...The authors need to mention the strength and limitation of the study

Response: In the last paragraph of the discussion section, we describe the strengths and limitations of this study.

Attachment

Submitted filename: Response to Reviewers.docx

pone.0303869.s003.docx (17KB, docx)

Decision Letter 1

Elvan Wiyarta

2 May 2024

Correlation between Novel Inflammatory Markers and Carotid Atherosclerosis: a Retrospective Case-control Study

PONE-D-23-42287R1

Dear Dr. qi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Elvan Wiyarta, M.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Ihave reviewed the article. It s a good study. I hope that the results will be beneficial.

thank you

sincerely yours

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Raw data

    (XLSX)

    pone.0303869.s001.xlsx (3.2MB, xlsx)
    Attachment

    Submitted filename: Minor Revision.docx

    pone.0303869.s002.docx (364.6KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0303869.s003.docx (17KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES